Transaction #23403 · Form 4 · 0001104659-25-123109
PALVELLA THERAPEUTICS, INC. · Exercise / conversion · Common Stock
PALVELLA THERAPEUTICS, INC. · Transacted December 17, 2025 · Filed December 19, 2025
What does this filing report?
An SEC Form 4 filing for PALVELLA THERAPEUTICS, INC. records an exercise / conversion involving Common Stock on December 17, 2025. The reported quantity was 2,154. The filing date is December 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- PALVELLA THERAPEUTICS, INC.
- Company CIK
- 0001583648
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 2,154
- Reported price
- 7.14
- Reference value
- 15,379.56
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 2,154
- Ownership description
- Not reported
- SEC acceptance time
- Dec 19, 2025, 4:05 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Goin Kathleen ↗
Chief Operating Officer
CIK 0001912570
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
- F2
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.34 to $96.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- F3
- The stock option is fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.